Anna Protopapas, Mersana Therapeutics CEO
J&J bets $40M cash on biotech's ADC tech and its battle-tested CEO — with biobucks adding to $1B
Trying to see if it can find new uses for a suite of antibodies its Janssen subsidiary has developed, J&J has tapped Mersana Therapeutics for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
